Section 10 · Monograph

Ramelteon

Reviewed Nov 2026FDA label

RozeremMelatonin receptor agonist

Indications

Treatment of insomnia characterized by difficulty with sleep onset, in adults.FDA-labeled

Circadian rhythm sleep-wake disorders (e.g., delayed sleep phase disorder, shift work disorder) — leverages MT1/MT2 agonism.Off-label
Preferred hypnotic option for insomnia in patients with a history of substance use disorder, given its non-scheduled status.Off-label
Adjunctive use for delirium prevention in hospitalized/ICU patients (studied in some trials, not an FDA-approved indication).Off-label

Ramelteon is a melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus, and comparatively low affinity for the MT3 receptor.
Agonism at MT1 and MT2 receptors is believed to promote sleep onset by reinforcing the endogenous circadian sleep-wake signal, distinct from GABAergic hypnotics.
Has no appreciable affinity for GABA-A receptors, opiate receptors, or other neurotransmitter binding sites tested — mechanistically distinct from benzodiazepines and the nonbenzodiazepine 'Z-drugs.'

Adults: 8 mg orally within 30 minutes of bedtime. Maximum recommended dose is 8 mg per day; higher doses have not shown greater efficacy.
Should not be taken with or immediately after a high-fat meal.
Not a controlled substance — no DEA schedule; abuse/dependence potential considered minimal, distinguishing it from Z-drugs and orexin antagonists.
May be considered for long-term nightly use given absence of dependence signal, but reassess ongoing benefit periodically; reevaluate if insomnia persists beyond 7-10 days.

History of angioedema following prior ramelteon use.
Concomitant use with fluvoxamine (strong CYP1A2 inhibitor — increases ramelteon AUC approximately 190-fold).
Severe hepatic impairment.

Fluvoxamine (strong CYP1A2 inhibitor): contraindicated — increases ramelteon AUC ~190-fold.
Rifampin (CYP inducer): decreases ramelteon exposure by ~80%, reducing efficacy — avoid combination.
Ketoconazole (strong CYP3A4 inhibitor) and fluconazole (CYP2C9 inhibitor): increase ramelteon exposure by ~84-150%.
Donepezil and doxepin: increase ramelteon exposure by ~66-100%.
Alcohol: additive psychomotor impairment — avoid concomitant use.
CNS depressants generally: potential additive sedative effects, though ramelteon's non-GABAergic mechanism generally confers a lower interaction/abuse liability profile than Z-drugs.

Somnolence, dizziness, fatigue, nausea — most common adverse reactions.
Exacerbation of insomnia.
Rare angioedema of the tongue, glottis, or larynx — risk of airway obstruction, potentially fatal.
Complex sleep behaviors, including reports of sleep-driving with amnesia for the event (less frequently reported than with Z-drugs; ramelteon does not carry the mandatory class boxed warning).
Neuroendocrine effects: decreased testosterone and increased prolactin levels with chronic use.
Behavioral changes and worsening of depression/suicidal ideation reported.
Discontinuation rate due to adverse events approximately 6% (vs 2% placebo).

Reassess if insomnia persists beyond 7-10 days.
Monitor for angioedema/anaphylaxis, particularly with first doses.
Monitor for behavioral changes, worsening depression, or emergent suicidal ideation.
Consider monitoring reproductive hormone levels (testosterone, prolactin) with long-term use if clinically indicated.
Assess for excessive daytime somnolence and counsel on hazardous activities/driving until effects are known.
Not recommended in patients with severe sleep apnea or severe COPD.
Screen for/avoid concomitant fluvoxamine use.

Pregnancy: Animal reproduction studies showed teratogenic and other adverse fetal effects at high doses. Limited human postmarketing data have not identified a drug-associated risk of major birth defects or miscarriage, but data are insufficient to fully define risk.
Lactation: Presence in human milk is unknown. Because of the potential for sedation in a breastfed infant, consider interrupting breastfeeding (pumping and discarding milk) for approximately 25 hours after a dose.